ASCO 2018 | IDH inhibitors for AML and MDS
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses exciting developments in IDH inhibitors for these diseases, including the FDA-approved IDH2 inhibitor enasidenib for use relapsed/refractory IDH2-mutated AML. Furthermore, she explores advancements in the use of the IDH1 inhibitor ivosidenib, a well tolerated agent with response rates of ~40% and complete remission rates of 20%. She holds the hope that we can add these options to our treatment repertoire to improve patient outcomes. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.
